

Supplementary Table 1. Summary of numbers of RNA edits observed in all RNA-seq experiments

Figure	Cell	BE	gRNA	Sort	Replicate	A-to-I (for ABE) or C-to-U (for CBE)	Other	A-to-I or C-to-U (%)	Mean Editing Efficiency	Median Editing Efficiency
Fig. 1b	HEK293T	ABEmax (data from Ref ⁵)	HEK site 2 (ABE site 1)	Top 5%	Rep. 1	37,059	87	99.77	22.5	18.8
					Rep. 2	16,049	201	98.76	22.1	17.7
					Rep. 3	27,706	246	99.12	22.1	18.3
		ABEmax	HEK site 2 (ABE site 1)	All GFP	Rep. 1	29,597	193	99.35	21.8	18.2
					Rep. 2	10,047	231	97.75	17.2	15.7
					Rep. 3	26,552	251	99.06	18.5	16.9
		miniABEmax	HEK site 2 (ABE site 1)	All GFP	Rep. 1	29,841	177	99.41	18.4	16.9
					Rep. 2	1,080	238	81.94	19.3	17.1
					Rep. 3	2,203	383	85.19	20.4	18.2
		miniABEmax-K20A/R21A	HEK site 2 (ABE site 1)	All GFP	Rep. 1	2,069	315	86.79	19.6	17.9
					Rep. 2	971	216	81.80	19.3	17.3
					Rep. 3	1,654	333	83.24	20.5	18.2
		miniABEmax-V82G	HEK site 2 (ABE site 1)	All GFP	Rep. 1	1,172	276	80.94	21.3	19.0
					Rep. 2	28,099	197	99.30	22.2	18.5
					Rep. 3	26,571	238	99.11	22.0	18.3
		ABEmax	ABE site 16	All GFP	Rep. 1	26,948	238	99.12	21.8	18.1
					Rep. 2	23,187	216	99.08	18.5	16.9
					Rep. 3	13,897	202	98.57	17.7	16.1
miniABEmax	ABE site 16	All GFP	Rep. 1	19,907	232	98.85	17.9	16.5		
			Rep. 2	1,376	292	82.49	20.2	17.9		
			Rep. 3	1,338	291	82.14	19.5	17.6		
miniABEmax-K20A/R21A	ABE site 16	All GFP	Rep. 1	1,696	295	85.18	19.1	17.1		
			Rep. 2	936	243	79.39	19.9	17.6		
			Rep. 3	1,224	336	78.46	18.9	16.7		
miniABEmax-V82G	ABE site 16	All GFP	Rep. 1	1,159	269	81.16	20.5	18.2		
			Rep. 2	15,909	202	98.75	22.2	17.9		
			Rep. 3	31,521	229	99.28	22.1	18.4		
ABEmax	NT	All GFP	Rep. 1	24,326	196	99.20	21.6	17.8		
			Rep. 2	8,748	379	95.85	17.6	16.1		
			Rep. 3	29,540	244	99.18	18.8	17.1		
miniABEmax	NT	All GFP	Rep. 1	25,426	261	98.98	18.4	16.9		
			Rep. 2	690	206	77.01	17.6	15.8		
			Rep. 3	2,102	325	86.61	20.6	18.2		
miniABEmax-K20A/R21A	NT	All GFP	Rep. 1	2,191	265	89.21	19.2	17.4		
			Rep. 2	762	143	84.20	18.3	16.7		
			Rep. 3	1,634	304	84.31	21.0	18.2		
miniABEmax-V82G	NT	All GFP	Rep. 1	1,582	282	84.87	18.6	16.7		
			Rep. 2	423	202	67.68	19.3	17.4		
			Rep. 3	270	175	60.67	17.6	16.0		
HEK293T	GFP	--	All GFP	Rep. 1	363	168	68.36	19.2	17.3	
				Rep. 2	31	131	19.14	18.0	15.8	
				Rep. 3	30,435	8	99.97	23.4	18.0	
hA3A-BE3	RNF2	Top 5%	MF-matched to top 5% BE3 expression	Rep. 1	27,190	8	99.97	23.3	18.0	
				Rep. 2	32,402	11	99.97	23.2	17.8	
				Rep. 3	98	101	49.25	19.6	16.1	
eA3A-BE3	RNF2	Top 5%	MF-matched to top 5% BE3 expression	Rep. 1	72	87	45.28	20.7	17.6	
				Rep. 2	113	78	59.16	22.2	17.3	
				Rep. 3	45	201	18.29	17.2	16.7	
hAID-BE3	RNF2	Top 5%	MF-matched to top 5% BE3 expression	Rep. 1	34	144	19.10	15.1	15.1	
				Rep. 2	70	234	23.03	16.1	15.4	
				Rep. 3	15	118	11.28	15.7	15.4	
Target-AID	RNF2	Top 5%	MF-matched to top 5% BE3 expression	Rep. 1	19	132	12.58	17.1	16.3	
				Rep. 2	10	60	14.29	14.0	14.6	
				Rep. 3	235	90	72.31	14.4	13.0	
BE3-R33A (data from Ref ⁵)	RNF2	Top 5%	MF-matched to top 5% BE3 expression	Rep. 1	355	111	76.18	17.0	15.4	
				Rep. 2	195	57	77.38	14.4	13.4	
				Rep. 3	20	77	20.62	13.6	15.4	
BE3-R33A/K34A (data from Ref ⁵)	RNF2	Top 5%	MF-matched to top 5% BE3 expression	Rep. 1	18	95	15.93	20.3	16.4	
				Rep. 2	7	42	14.29	17.3	13.6	
				Rep. 3	7	42	14.29	17.3	13.6	

Supplementary Table 2. Summary of numbers of BE-induced self-edits and gRNA edits

Cell	BE	gRNA	Sort	Replicate	Number of BE self-edits				Number of gRNA edits	
					Nonsense	Missense	Synonymous	Total		
HEK293T	WT BE3	<i>RNF2</i>	All GFP	Rep. 1	11	44	70	125	0	
				Rep. 2	8	25	51	84	0	
				Rep. 3	10	38	57	105	0	
	WT BE3	<i>EMX1</i>	All GFP	Rep. 1	6	32	56	94	0	
				Rep. 2	9	29	45	83	0	
				Rep. 3	6	31	50	87	0	
HEK293T	WT BE3	<i>RNF2</i>	Top 5%	Rep. 1	14	55	80	149	0	
				Rep. 2	15	64	98	177	0	
				Rep. 3	15	57	83	155	0	
	BE3-R33A	<i>RNF2</i>	Top 5%	Rep. 1	0	0	0	0	0	
				Rep. 2	0	0	0	0	0	
				Rep. 3	0	0	0	0	0	
	BE3-R33A/K34A	<i>RNF2</i>	Top 5%	Rep. 1	0	0	0	0	0	
				Rep. 2	0	0	0	0	0	
				Rep. 3	0	0	0	0	0	
	HepG2	WT BE3	<i>RNF2</i>	Top 5%	Rep. 1	10	37	66	113	0
					Rep. 2	10	35	56	101	0
					Rep. 3	8	45	62	115	0
BE3-R33A		<i>RNF2</i>	Top 5%	Rep. 1	0	0	0	0	0	
				Rep. 2	0	0	0	0	0	
				Rep. 3	0	0	0	0	0	
BE3-R33A/K34A		<i>RNF2</i>	Top 5%	Rep. 1	0	0	0	0	0	
				Rep. 2	0	0	0	0	0	
				Rep. 3	0	0	0	0	0	
HEK293T		hA3A-BE3	<i>RNF2</i>	Top 5%	Rep. 1	6	5	17	28	0
					Rep. 2	6	5	17	28	0
					Rep. 3	6	6	19	31	0
	eA3A-BE3	<i>RNF2</i>	Top 5%	Rep. 1	0	0	0	0	0	
				Rep. 2	0	0	0	0	0	
				Rep. 3	0	0	0	0	0	
	hAID-BE3	<i>RNF2</i>	Top 5%	Rep. 1	0	0	0	0	0	
				Rep. 2	0	0	0	0	0	
				Rep. 3	0	0	0	0	0	
	Target-AID	<i>RNF2</i>	Top 5%	Rep. 1	0	0	0	0	0	
				Rep. 2	0	0	0	0	0	
				Rep. 3	0	0	0	0	0	
HEK293T	ABEmax	HEK site 2 (ABE site 1)	All GFP	Rep. 1	—	36	3	39	0	
				Rep. 2	—	54	3	57	0	
				Rep. 3	—	60	4	64	0	
	miniABEmax	HEK site 2 (ABE site 1)	All GFP	Rep. 1	—	33	2	35	1	
				Rep. 2	—	53	4	57	1	
				Rep. 3	—	61	3	64	1	
	miniABEmax-K20A/R21A	HEK site 2 (ABE site 1)	All GFP	Rep. 1	—	0	1	1	0	
				Rep. 2	—	2	1	3	0	
				Rep. 3	—	1	1	2	1	
	miniABEmax-V82G	HEK site 2 (ABE site 1)	All GFP	Rep. 1	—	0	0	0	1	
				Rep. 2	—	0	0	0	1	
				Rep. 3	—	0	0	0	1	
HEK293T	ABEmax	ABE site 16	All GFP	Rep. 1	—	51	3	54	0	
				Rep. 2	—	48	4	52	1	
				Rep. 3	—	48	2	50	0	
	miniABEmax	ABE site 16	All GFP	Rep. 1	—	41	3	44	1	
				Rep. 2	—	33	2	35	1	
				Rep. 3	—	37	2	39	1	
	miniABEmax-K20A/R21A	ABE site 16	All GFP	Rep. 1	—	0	1	1	1	
				Rep. 2	—	0	1	1	1	
				Rep. 3	—	1	1	2	1	
	miniABEmax-V82G	ABE site 16	All GFP	Rep. 1	—	0	0	0	1	
				Rep. 2	—	0	0	0	1	
				Rep. 3	—	0	0	0	1	
HEK293T	ABEmax	NT	All GFP	Rep. 1	—	37	2	39	0	
				Rep. 2	—	54	4	58	0	
				Rep. 3	—	59	4	63	0	
	miniABEmax	NT	All GFP	Rep. 1	—	29	2	31	1	
				Rep. 2	—	63	5	68	1	
				Rep. 3	—	62	4	66	1	
	miniABEmax-K20A/R21A	NT	All GFP	Rep. 1	—	1	1	2	0	
				Rep. 2	—	2	1	3	0	
				Rep. 3	—	2	1	3	0	
	miniABEmax-V82G	NT	All GFP	Rep. 1	—	0	0	0	1	
				Rep. 2	—	0	0	0	1	
				Rep. 3	—	0	0	0	1	

Supplementary Note 1.

The ABE 7.10 variant, on which ABEmax is based, was derived through a successive series of engineering steps with different variants numbered sequentially as alterations were made¹. The second (wild-type) TadA domain was added to ABE 2.6 and then the subsequent 47 iterations of optimization that led to ABE 7.10 were performed on a dimeric TadA architecture (Extended Data Fig. 1 of Ref. 1). ABE 2.1 (which lacked the additional wild-type TadA) possessed comparable editing efficiencies to the heterodimeric architecture of the same variant, ABE 2.10 (Fig. 3a of Ref. 1). Thus, even at this early stage of the engineering process, the additional wild-type TadA domain was not required to enable programmable A-to-G DNA base editing. In addition, the subsequent 47 stages of directed evolution and optimization leading to the final variant ABE 7.10 might have yielded a TadA* variant with greatly improved DNA editing capabilities that might therefore even be less dependent on the presence of a linked TadA domain. Finally, because ABEmax is a codon optimized version of the ABE7.10 variant, it is possible that the enhanced expression of this base editor might partially rescue a moderate loss of DNA base editing activity.

Reference:

1. Gaudelli, N. M. *et al.* Programmable base editing of A*T to G*C in genomic DNA without DNA cleavage. *Nature* **551**, 464-471, doi:10.1038/nature24644 (2017).


Supplementary Note 2. FACS gating examples for GFP cell sorting conditions.

Please find attached representative FACS plot data (batch analysis output) demonstrating how control and base editor expressing HEK293T cells were sorted. All data were generated at the MGH Molecular Pathology Flow Cytometry Core Facility on a BD FACSAria II cytometer using BD FACSDiva software (version 6.1.3). We exclusively sorted GFP+ cells.


The depicted dot plots were used for doublet exclusion as well as gating for the cell population and the GFP+ cells being sorted. FITC (x-axis) is a fluorochrome that closely matches the spectral characteristics of GFP.

FACS Raw Data Analysis Legends


BD FACSDiva 6.1.3
Batch Analysis




HEK293T Negative Control (no transfection)




HEK293T All GFP+ nCas9 Control for ABE




HEK293T All GFP+
ABEmax treated



HEK293T All GFP+
miniABEmax treated




HEK293T Top 5%-matched nCas9 Control for CBE



5% population with **GeoMean (MFI)** matched to top 5% BE-treated cells (see next slide)

HEK293T Top 5% CBE-treated



Top 5% signal population & **GeoMean (MFI)**

HEK293T Top 5%-matched GFP Control

